NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
2.590
-0.350 (-11.90%)
At close: Sep 12, 2025, 4:00 PM EDT
2.650
+0.060 (2.31%)
After-hours: Sep 12, 2025, 8:00 PM EDT
Company Description
NovaBay Pharmaceuticals, Inc. does not have significant operations.
Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally.
The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
NovaBay Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2000 |
| IPO Date | Oct 26, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Justin Hall |
Contact Details
Address: 2000 Powell Street, Suite 1150, eleventh floor Emeryville, California 94608 United States | |
| Phone | 510 899 8800 |
| Website | novabay.com |
Stock Details
| Ticker Symbol | NBY |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001389545 |
| CUSIP Number | 66987P201 |
| ISIN Number | US66987P4090 |
| Employer ID | 68-0454536 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Justin M. Hall Esq., J.D. | President, Chief Executive Officer, General Counsel, Chief Compliance Officer, Corporate Secretary and Director |
| Tommy Law | Controller, Interim Chief Financial Officer and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 10, 2025 | PRE 14A | Other preliminary proxy statements |
| Sep 4, 2025 | SCHEDULE 13D/A | Filing |
| Aug 26, 2025 | SCHEDULE 13D | Filing |
| Aug 26, 2025 | 8-K | Current Report |
| Aug 19, 2025 | 8-K | Current Report |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Jun 4, 2025 | SCHEDULE 13D | Filing |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| Apr 22, 2025 | 8-K | Current Report |